Kevin Felice
Neuromuscular Medicine · New Britain, CTNPI 1033114889
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,664 of the $2,343 with a category attached, or 71.0%. 13 manufacturers reported payments, led by UCB SA at 35.6% of the total. Reporting peaked in 2019 at $1,026 and has fallen 89.7% since, to $106 in 2025.
Across 96 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$835
- Xeris Pharmaceuticals, Inc.$521
- Amneal Pharmaceuticals LLC$219
- Strongbridge US Inc.$170
- Neurocrine Biosciences, Inc.$134
- Avanir Pharmaceuticals, Inc.$105
- plus $360 from 7 others
Across 42 payments — averaging $11,214 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$247K
- Orion Corporation$216K
- Biohaven Pharmaceutical Holding Company Ltd.$8K
What the payments were for
- Travel & lodging$67929%
- Food & beverage$1,66471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 6 | $835 |
| Xeris Pharmaceuticals, Inc. | 28 | $521 |
| Amneal Pharmaceuticals LLC | 14 | $219 |
| Strongbridge US Inc. | 16 | $170 |
| Neurocrine Biosciences, Inc. | 5 | $134 |
| Avanir Pharmaceuticals, Inc. | 6 | $105 |
| Adamas Pharmaceuticals, Inc. | 7 | $104 |
| Tanabe Pharma America, Inc. | 5 | $100 |
| Acadia Pharmaceuticals Inc | 5 | $83 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Amylyx Pharmaceuticals, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
How this compares
Too few neuromuscular medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $294,042 |
| Pregabalin | 11 | $158 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in New Britain
- Annie DanielNew Britain$312
- John TauroNorwich$54K
- Sasa ZivkovicGuilford$37K
- Bhaskar RoyNew Haven$17K
- Barry GordonMeriden$3K
- David TinklepaughMystic$2K
- Ylec Cardenas CastilloNew Haven$1K
- Arpad FejosMiddletown$1K
- Bilal HameedNew London$1K
- Zara KhanWestport$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.